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We have designed, developed and produced a lambda-
phage based anti-cancer vaccine (nano-particle) targeting
human aspartyl (asparaginyl) b-hydroxylase (HAAH). This
follows accumulated evidence that HAAH meets require-
ments of a good target for anti-cancer immunotherapy.
The protein is over-expressed on the surface of cancer
cells and plays a central role in cancer etiology that effects
cancer cell growth, motility and invasiveness. Over-
expression of HAAH in transfected normal cells is suffi-
cient to induce cellular transformation, and suppression of
HAAH expression (siRNA) or neutralized activity (mAb)
returns cancer cells to a normal phenotype. Moreover,
tumor growth in xenograft models of human liver and
lung cancer is significantly (>80%) inhibited by administra-
tion of anti-HAAH monoclonal antibodies. Therefore, it is
expected that a patient polyclonal antibody response
against HAAH should result in a significant therapeutic
effect. HAAH is an embryonic protein and as such is a self
antigen. Moreover, it has been observed that the HAAH
gene is well conserved and mouse AAH has very high
homology in the N-terminal portion of HAAH and com-
plete homology in the mid and C-terminal portion.
Historically, recombinant HAAH protein administered
with adjuvants has not proven to be very immunogenic in
mice. Here we have used immunocompetent mice to test
immunogenicity of three phage-based vaccine candidates,
encompassing the N-terminal, mid and C-terminal
portions of the HAAH extracellular domain. All three
entities display highly significant, dose-dependent immu-
nogenicity. Animals were injected with 5x107-5x109 pfus
on days 0, 7 and 14. Animals were bled on day 21 and
immunogenicity was screened using recombinant HAAH
in an ELISA format. Cell-based ELISAs using liver
(FOCUS) and lung (H460) cancer cell lines as well as
FACS analysis on these lines were performed. The immu-
nized mice sera had clear anti-HAAH (or anti-cancer cell)
activity in all tests. Immunogenicity was dose and
construct dependent. This work demonstrates that a
nano-particle, phage-based vaccine can break immune
tolerance to the native HAAH protein and elicit a specific
antibody response; indicating that such vaccines may have
significant therapeutic value. Indeed preliminary data from
an ongoing animal study testing this vaccine in a mouse
tumor model has demonstrated a quick and very signifi-
cant anti-tumor activity, slowing the growth of subcuta-
neously implanted mouse liver cancer tumors. Thus, this
strategy of expressing portions of the HAAH protein on
the surface of lambda-phage has resulted in overcoming
tolerance to self antigen and promises to be an effective
anti-cancer vaccine.
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